Overview
- AstraZeneca formally opened the 18‑storey, 570,000 sq ft research centre at 290 Binney Street on Monday, Oct. 5, 2026, with a ribbon‑cutting in Kendall Square.
- The building contains ten floors of interconnecting laboratories built for high‑throughput work and is designed to integrate with the nearby 100 Binney Street genomic medicine site.
- Company and local reporting say about 1,100 staff will be on site by the end of 2026 and AstraZeneca plans to grow its Massachusetts headcount to roughly 3,000 over the next few years.
- AstraZeneca highlights the use of robotics, continuous automation and agentic AI to speed candidate discovery in oncology, cell therapy, chronic and rare‑disease programs.
- The $1 billion Massachusetts investment is part of a wider $50 billion U.S. plan and is meant to strengthen Kendall Square’s life‑sciences cluster while boosting local hiring, academic partnerships and biotech competitiveness.